Emil D. Kakkis
President & CEO · Ultragenyx Pharmaceutical Inc.
- 2024
- Apr 20, 2026
- 4
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Emil D. Kakkis files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Howard Horn - $1.08M in RARE purchases and sales in the last 12 months
- Karah Herdman Parschauer - $488K in RARE purchases and sales in the last 12 months
- Erik Harris - $240K in RARE purchases and sales in the last 12 months
- John Richard Pinion - $229K in RARE purchases and sales in the last 12 months
- Eric Crombez - $169K in RARE purchases and sales in the last 12 months
- Shehnaaz Suliman - $144K in RARE purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Emil D. Kakkis?
Emil D. Kakkis is a corporate insider, tracked as President & CEO of Ultragenyx Pharmaceutical Inc. (RARE). InsiderAlpha holds 4 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
When did Emil D. Kakkis last file a Form 4?
The most recent primary Form 4 on record is dated 20 April 2026, one of 4 filings going back to 2024.
Has Emil D. Kakkis been buying or selling stock?
Recorded transactions: 0 open-market purchases and 3 open-market sales ($2.15M) across all tracked filings.
